NCT00245011View on ClinicalTrials.gov

Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma

PHASE2CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

March 31, 2009

Conditions
Sarcoma
Interventions
BIOLOGICAL

filgrastim

Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.

DRUG

ifosfamide

Ifosfamide administered IV.

PROCEDURE

peripheral blood stem cell transplantation

Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered

RADIATION

Sm-EDTMP (low dose)

Sm-EDTMP (low dose) administered after autologous stem cell collection

RADIATION

sm-EDTMP (higher dose)

Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00245011 - Samarium Sm 153 and Stem Cell Transplant Followed By Radiation Therapy Patients With Osteosarcoma | Biotech Hunter | Biotech Hunter